-
Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy.
Khalil A, Akolekar R, Pandya P, Syngelaki A, Nicolaides K.
Obstet Gynecol 2010;116:374-80. -
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:542-7. -
Prospective validation of first-trimester combined screening for trisomy 21.
Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;34:14-8. -
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:259-64. -
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation.
Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:18-22. -
The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
Cowans NJ, Stamatopoulou A, Maiz N, Spencer K, Nicolaides KH.
Prenat Diagn 2009;29:578-81. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH.
Obstet Gynecol 2008;31:147-52. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:488-92. -
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:618-24. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;28:637-43. -
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:151-5. -
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50.